CNIC scientists identify a biomarker that improves risk prediction in a severe form of heart failure

The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease severity, mortality, and heart failure events.

The study shows that disease severity and poor prognosis in ATTR-CM are associated with elevated levels of mid-regional pro-adrenomedullin (MR-proADM), a biomarker associated with disease severity across a broad range of conditions, including sepsis. This finding could help identify high-risk patients more precisely. The study was led by Dr. Pablo García-Pavía, leader of the Hereditary Cardiomyopathies group at the CNIC, a cardiologist at Hospital Puerta de Hierro, and a member of the Spanish cardiovascular research network (CIBERCV).